Nuclear ErbB3 Predicts Sensitivity to Androgen Receptor Inhibitors in Castration-Resistant Prostate Cancer

Abstract

This research focuses on ErbB3, a member of the epidermal growth factor receptor (EGFR)family in castration-resistant prostate cancer (CRPC), and the role that its localization may play by altering efficacy of AR inhibitors (AR-I) in prostate cancer (CaP). In Aim 1 we willinvestigate whether subcellular localization of ErbB3 renders CaP cells resistant or responsive to AR-I. In Aim 2 we will investigate whether secondary markers of ErbB3localization can predict response or resistance to AR-I. We have thus demonstrated that some metastatic, hormone-sensitive prostate tumors show increased efficacy towards AR-I when ErbB3is silenced. Our overall goal is understanding whether ErbB3 can predict which patients will benefit most from treatment with AR-I.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2022
Accession Number
AD1172656

Entities

People

  • Maitreyee K. Jathal

Organizations

  • University of California

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • California
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Culture Techniques
  • Inhibitors
  • Maryland
  • Materials
  • Medical Personnel
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Proteins
  • United States

Readers

  • Molecular Biology and Genetics
  • Prostate Cancer Biology.